Email from my Imusil inquiry

Click here for my first post on Imusil.

Below is an email receipt from my later inquiry.
It appears they're going for FDA approval.

What a waste...of millions of dollars and years of
testing.

From: IMPY@NETVISION.NET.IL
Marvin

To: jomama
Subject: Fw: Imusil Inquiries.


Date: Thu, 09 Dec 2004 13:38:31 -0800

STATEMENT ON TETRASIL® AND IMUSIL®
-------------------------------------------------

Thank your for your interest in Aidance
products, makers of Tetrasil® Multi-Purpose
Topical Ointment, www.Tetrasil.com

The Imusil® product, for treatment of HIV and
AIDS, is still under development.

It is essential that the proper clinical studies
be made to guarantee the treatment's efficacy and
safety. Premature use, before the proper
protocols are established, could jeopardize a
patient's health, the product's development, and
delay its introduction to the general public.

At Aidance, we certainly take very seriously the
grave and compelling conditions of individuals
battling HIV and AIDS. However, in order to help
the most people in the safest way, we need to
proceed in a responsible fashion. To achieve
this, and bring the product to market, we are
seeking investors, institutions, and donors to
fund the proper studies and clinical trials.

If you know any potential investors (minimum
$50K) who may be interested in our efforts,
please refer them to us. You will be doing a
great service to the world. These potential
stakeholders may reach us at
aht_info@marantech.com or call at (401) 223-3000.
In the future, as more information becomes
available, it will be published on www.Imusil.com.

Sincerely,

Aidance Management



ADDITIONAL FAQ's ANSWERED
-------------------------------------------------
Aidance has made no claims about an injectable
form. We are hoping to conduct double blind
clinical trials in the near future (funding
dependent). There was an offshore clinical study
on a "Compassionate Care" basis, of an injectable
form of the active ingredient Tetrasilver
Tetroxide (TsT). Even though the data gathering
protocols were not followed to Aidance's
satisfaction, and results were inconclusive by
U.S. standards, the results were nonetheless
encouraging. Imusil® is the current product now
being developed with TsT for treating internal,
systemic and life-threatening conditions.

Tetrasil's current formulation is to treat
topical pathogens causing unwanted skin
conditions only. HIV is a systemic life
threatening condition beyond the scope of the
Tetrasil® topical ointment. FDA approval process
has not yet been sought for Tetrasil® topical
ointment or the Imusil product (still under
development).

Aidance is confident in the safety of the
topical usage based on the success of earlier
dermal, oral, ocular, ingestion toxicity and
genotoxicity studies of the active ingredient,
Tetrasilver Tetroxide (TsT). The success rate of
TsT against a broad spectrum of pathogens for in-
vitro experiments is very high. The anecdotal
evidence from users of Tetrasil® is also very
convincing.

While Imusil® is not yet available, the
Tetrasil® product for topical application may
offer significant relief to HIV and AIDS patients
contending with a variety of topical skin
conditions.

Thank you.